The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells

Annals of the Rheumatic Diseases

Volumn 73, Issue 12, 2014, Pages 2192-2198

  Kubo, Satoshi ^a   Yamaoka, Kunihiro ^a   Kondo, Masahiro ^a   Yamagata, Kaoru ^a   Zhao, Jidong ^a   Iwata, Shigeru ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD45RA ANTIGEN; CD86 ANTIGEN; HLA DR ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE 2; INTERFERON; INTERFERON RECEPTOR; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE 3; MESSENGER RNA; TOFACITINIB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CD86 PROTEIN, HUMAN; IL1B PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; COCULTURE; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MONOCYTE DERIVED DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

ANTIGENS, CD80; ANTIGENS, CD86; CELL DIFFERENTIATION; DENDRITIC CELLS; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; JANUS KINASE 3; LYMPHOCYTE ACTIVATION; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883588577     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203756     Document Type: Article

References (46)

1. Ghoreschi K, Laurence A. O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009; 228: 273-87.
2. Müller-Ladner U, Judex M, Ballhorn W, et al. Activation of the IL-4 STAT pathway in rheumatoid synovium. J Immunol 2000; 164: 3894-901.
3. Li WQ, Dehnade F, Zafarullah M. Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. J Immunol 2001; 166: 3491-8.
4. Frucht DM, Aringer M, Galon J, et al. Stat4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1-mediated inflammation. J Immunol 2000; 164: 4659-64.
5. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127-32.
6. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by Tofacitinib (CP-690,550). J Immunol 2011; 186: 4234-43.
7. Kremer JM, Cohen S, Wilkinson BE, et al. A Phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate alone. Arthritis Rheum 2011; 64: 970-8.
8. Tanaka Y, Suzuki M, Nakamura H, et al. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011; 63: 1150-8.
9. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009; 60: 1895-905.
10. Coombs JH, Bloom BJ, Breedveld FC, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2010; 69: 413-16.
11. Kuwana M. Induction of anergic and regulatory T cells by plasmacytoid dendritic cells and other dendritic cell subsets. Hum Immunol 2002; 63: 1156-63.
12. Kretschmer K, Apostolou I, Hawiger D, et al. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 2005; 6: 1219-27.
13. Chen M, Wang Y, Wang Y, et al. Dendritic cell apoptosis in the maintenance of immune tolerance. Science 2006; 311: 1160-4.
14. Jung S, Unutmaz D, Wong P, et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 2002; 17: 211-20.
15. Whartenby K, Calabresi P, McCadden E, et al. Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc Natl Acad Sci USA 2005; 102: 16741-6.
16. Teichmann LL, Ols ML, Kashgarian M, et al. Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity 2010; 33: 967-78.
17. Maeshima K, Yamaoka K, Kubo S, et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells. Arthritis Rheum 2012; 64: 1790-8.
18. Yamaoka K, Min B, Zhou Y, et al. Jak3 negatively regulates dendritic-cell cytokine production and survival. Blood 2005; 106: 3227-33.
19. Wenink MH, Santegoets KC, Butcher J, et al. Impaired dendritic cell proinflammatory cytokine production in psoriatic arthritis. Arthritis Rheum 2011; 63: 3313-22.
20. Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, et al. The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum 2005; 52: 2313-22.
21. Martin CA, Carsons SE, Kowalewski R, et al. Aberrant extracellular and dendritic cell (DC) surface expression of heat shock protein (hsp)70 in the rheumatoid joint: possible mechanisms of hsp/DC-mediated cross-priming. J Immunol 2003; 171: 5736-42.
22. Walker J, Ahern M, Coleman M, et al. Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 992-9.
23. Walker J, Ahern M, Coleman M, et al. Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. Ann Rheum Dis 2006; 65: 1558-64.
24. Walker J, Ahern M, Coleman M, et al. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis 2006; 65: 149-56.
25. Changelian PS, Moshinsky D, Kuhn CF, et al. The specificity of JAK3 kinase inhibitors. Blood 2008; 111: 2155-7.
26. Kiss R, Polgár T, Kirabo A, et al. Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. Bioorg Med Chem Lett 2009; 19: 3598-601.
27. Steele AJ, Prentice AG, Cwynarski K, et al. The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment. Blood 2010; 116: 4569-77.
28. Hanke JH, Gardner JP, Dow RL, et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 1996; 271: 695-701.
29. Yamaoka K, Otsuka T, Niiro H, et al. Activation of STAT5 by lipopolysaccharide through granulocyte-macrophage colony-stimulating factor production in human monocytes. J Immunol 1998; 160: 838-45.
30. Betts BC, St Angelo ET, Kennedy M, et al. Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses. Blood 2011; 118: 5340-3.
31. Zou GM, Hu WY. LIGHT regulates CD86 expression on dendritic cells through NF-kappaB, but not JNK/AP-1 signal transduction pathway. J Cell Physiol 2005; 205: 437-43.
32. Kanada S, Nishiyama C, Nakano N, et al. Critical role of transcription factor PU.1 in the expression of CD80 and CD86 on dendritic cells. Blood 2011; 117: 2211-22.
33. Lim W, Gee K, Mishra S, et al. Regulation of B7.1 costimulatory molecule is mediated by the IFN regulatory factor-7 through the activation of JNK in lipopolysaccharide-stimulated human monocytic cells. J Immunol 2005; 175: 5690-700.
34. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762-74.
35. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508-19.
36. Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013; 381: 451-60.
37. van Vollenhoven RF. Small molecular compounds in development for rheumatoid arthritis. Curr Opin Rheumatol 2013; 25: 391-7.
38. Baldwin H, Ito-Ihara T, Isaacs J, et al. Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1200-7.
39. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2: 675-80.
40. Lodie TA, Savedra R, Golenbock DT, et al. Stimulation of macrophages by lipopolysaccharide alters the phosphorylation state, conformation, and function of PU.1 via activation of casein kinase II. J Immunol 1997; 158: 1848-56.
41. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511.
42. Sato M, Suemori H, Hata N, et al. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity 2000; 13: 539-48.
43. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999; 20: 469-73.
44. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191-3.
45. Maroof A, Penny M, Kingston R, et al. Interleukin-4 can induce interleukin-4 production in dendritic cells. Immunology 2006; 117: 271-9.
46. Musso T, Gusella GL, Brooks A, et al. Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression in human monocytes. Blood 1994; 83: 1408-11.